Press Releases

Media Inquiries - media@caredxinc.com

Date	Title and Summary	Additional Formats
Toggle Summary May 09, 2018	CareDx expands NGS Transplant Product Offerings License and Commercialization Agreement with Illumina BRISBANE, Calif. , May 09, 2018 (GLOBE NEWSWIRE) -- CareDx (NASDAQ:CDNA), today announced that, as reported in its Current Report on Form 8-K filed with the Securities Exchange Commission on May 8, 2018 , it entered into a License and	View HTML
Toggle Summary May 01, 2018	CareDx Activities at American Transplant Congress BRISBANE, Calif. , May 01, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, will highlight the first and only	View HTML
Toggle Summary Apr 20, 2018	CareDx to Announce First Quarter 2018 Financial Results on May 10, 2018 BRISBANE, Calif. , April 20, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release	View HTML
Toggle Summary Apr 18, 2018	CareDx Closes Debt Refinancing $15 Million Term Loan with Perceptive Advisors BRISBANE, Calif. , April 18, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant	View HTML
Toggle Summary Apr 13, 2018	Olerup QTYPE® Receives CE Mark Certification Fastest real time typing with Olerup QTYPE is now broadly available BRISBANE, Calif. , April 13, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic	View HTML
Toggle Summary Apr 10, 2018	CareDx Launches HeartCare® for Heart Transplant Recipients HeartCare combines AlloMap and AlloSure-Heart for Comprehensive Rejection Surveillance BRISBANE, Calif. , April 10, 2018 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated,	View HTML
Toggle Summary Mar 29, 2018	CareDx Announces Completion of Debt Conversion Further Balance Sheet Simplification BRISBANE, Calif. , March 29, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients,	View HTML
Toggle Summary Mar 22, 2018	CareDx Reports Fourth Quarter and FY2017 Financial Results 47 Transplantation Centers Offering AlloSure 9 Centers Enrolled in K-OAR BRISBANE, Calif. , March 22, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic	View HTML
Toggle Summary Mar 06, 2018	CareDx to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on March 22, 2018 BRISBANE, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release	View HTML
Toggle Summary Mar 01, 2018	CareDx to Refinance Debt with Perceptive Advisors Balance Sheet to be Simplified with Single Term Loan BRISBANE, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- CareDx , Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for	View HTML